Homegrown trailblazers! Brian Wolpin/Andy Aguirre, Jim Griffin/Rich Stone, Eric Smith/Omar Nadeem! @DFCIMedOnc faculty retreat
Amazing retrospective from Jim Griffin and Rich Stone on the development of FLT3 inhibitors for AML, at the Dana-Farber Dept of Medical Oncology faculty retreat.
4
345
Mahasweta Gooptu retweeted
Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia
Outstanding work by @LuskinMarlise @DanaFarber @ShaiShimony et al.
ashpublications.org/blood/ar…
Amazing!!
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
1
86
Congratulations Moses!! Rising star at DFCI @haematognomist @DanaFarberNews
Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: ow.ly/fQ5G50Y9q2J
153
Transplant Jedi. :D @DrCCutler @miguelperales
Congratulations to our 2026 Fellows of ASTCT and past presidents Dr. Corey Cutler and Dr. Miguel-Angel Perales! #Tandem26 @DrCCutler
6
310
Amazing team effort and leadership!! @DrCCutler
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: bit.ly/4pHA7EJ
2
102
G.O.A.T. :D
Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty. We thank Dr. Soiffer for his continued dedication and leadership, which truly exemplify this honor.
2
101
80% 1 year overall survival in mismatched unrelated donor transplants all the way down to 4/8 mismatched donors!! #Donorsforall #solvedisparitieswithscience @BrianShafferMD @BronwenShaw @nmdp_org
Dr. Mahasweta Gooptu (@MGooptu) @danafarber &@nmdp_org presented results using post-transplant cyclophosphamide to prevent graft-versus-host disease in mismatched unrelated donor transplantation, with about 80% 1-year survival thus expanding access to allotransplant for all patients. #ASH25
2
153
Mahasweta Gooptu retweeted
CONGRESS | #ASH2025 | POSTER
Mahasweta Gooptu shares results from a Phase II expansion study focusing on PTCy-based GVHD prophylaxis after MMUD PBSC transplantation with reduced-intensity conditioning (N = 193).
The 1-year OS estimate was 79.6%; rates were comparable between HLA 7/8-matched donor recipients and <7/8 matched donor recipients. The 1-year GRFS, 1-year PFS, 1-year CI rate of NRM, and 1-year CI rate of relapse was 49.9%, 70.2%, 12.5%, and 17.3%, respectively.
Follow our live feed for more updates: loom.ly/MbPzIiA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @MGooptu @DanaFarber
Mahasweta Gooptu retweeted
Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every patient. #ADonorForAll #PTCyRules
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/ar…
Mahasweta Gooptu retweeted
India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.
Mahasweta Gooptu retweeted
Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.
Mahasweta Gooptu retweeted
Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.
bit.ly/3X05jmp
Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). @DrCCutler @DanaFarberNews
Mahasweta Gooptu retweeted
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/ar…
by Dr. Luskin et al. #leusm #ALL
100% CR.
At day 84, 100% of patients achieved complete cytogenetic remission.
At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.
Mahasweta Gooptu retweeted
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer:
How I Treat AML relapse after allogeneic HCT:
ashpublications.org/blood/ar…
No one-size fits all approach to this challenging situation, learned a ton writing it!
Great experience collaborating with Moses for this review!! Star mentees make our jobs easy :) @haematognomist
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer:
How I Treat AML relapse after allogeneic HCT:
ashpublications.org/blood/ar…
No one-size fits all approach to this challenging situation, learned a ton writing it!
Mahasweta Gooptu retweeted
🚨 New findings from the @BMTCTN 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported #GVHD symptom burden vs Tac/MTX in the first year after transplant. 📊🩺 #PTCyRules Congrats, team!! 💪 @GvHD_Meade @MediHumdani
ascopubs.org/doi/10.1200/JCO…




































